These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19643213)

  • 21. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response.
    Mukhopadhaya A; Mahalanabis D; Chakrabarti MK
    Vaccine; 2006 Aug; 24(33-34):6028-36. PubMed ID: 16765491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study.
    Hannu T; Mattila L; Siitonen A; Leirisalo-Repo M
    Ann Rheum Dis; 2005 Apr; 64(4):594-8. PubMed ID: 15550534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?
    Phalipon A; Mulard LA; Sansonetti PJ
    Microbes Infect; 2008 Jul; 10(9):1057-62. PubMed ID: 18672087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shigella vaccine development: prospective animal models and current status.
    Kim YJ; Yeo SG; Park JH; Ko HJ
    Curr Pharm Biotechnol; 2013; 14(10):903-12. PubMed ID: 24372251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vaccination against diarrheal diseases and typhoid fever. Current status and prospects].
    Ivanoff B; Neira M
    Ann Med Interne (Paris); 1998 Oct; 149(6):340-50. PubMed ID: 9853044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Lu T; Das S; Howlader DR; Picking WD; Picking WL
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children.
    Walker RI
    Vaccine; 2015 Feb; 33(8):954-65. PubMed ID: 25482842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Willingness to be vaccinated against shigella and other forms of dysentery: a comparison of three regions in Asia.
    Pack R; Wang Y; Singh A; von Seidlein L; Pach A; Kaljee L; Butraporn P; Youlong G; Blum L; Bhutta Z; Santoso SS; Trach DD; Waluyo I; Nyamete A; Clemens J; Stanton B
    Vaccine; 2006 Jan; 24(4):485-94. PubMed ID: 16137802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
    Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
    Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination vaccine strategies to prevent enteric infections.
    Walker R; Dull P
    Vaccine; 2017 Dec; 35(49 Pt A):6790-6792. PubMed ID: 28705515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current aspects of Shigella pathogenesis.
    Torres AG
    Rev Latinoam Microbiol; 2004; 46(3-4):89-97. PubMed ID: 17061529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress and pitfalls in Shigella vaccine research.
    Barry EM; Pasetti MF; Sztein MB; Fasano A; Kotloff KL; Levine MM
    Nat Rev Gastroenterol Hepatol; 2013 Apr; 10(4):245-55. PubMed ID: 23419287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high incidence of Shigella-induced arthritis in a primate species: major histocompatibility complex class I molecules associated with resistance and susceptibility, and their relationship to HLA-B27.
    Urvater JA; McAdam SN; Loehrke JH; Allen TM; Moran JL; Rowell TJ; Rojo S; López de Castro JA; Taurog JD; Watkins DI
    Immunogenetics; 2000 Apr; 51(4-5):314-25. PubMed ID: 10803844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial epitopes involved in the induction of reactive arthritis.
    Stieglitz H; Fosmire S; Lipsky PE
    Am J Med; 1988 Dec; 85(6A):56-8. PubMed ID: 2462352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of immunization against bacterial enteric infections (author's transl)].
    Rey M
    Med Trop (Mars); 1979; 39(4):457-62. PubMed ID: 537492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New vaccines against enteric bacteria for children in less developed countries.
    Walker RI
    Expert Rev Vaccines; 2005 Dec; 4(6):807-12. PubMed ID: 16372876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin.
    Suzuki T; Yoshikawa Y; Ashida H; Iwai H; Toyotome T; Matsui H; Sasakawa C
    J Immunol; 2006 Oct; 177(7):4709-17. PubMed ID: 16982910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.